Objetivo Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). However, although surgical techniques and postoperative care have greatly advanced, renal transplantation is not empty of challenges.The most important challenge is to achieve the long-term survival of the transplanted organ. Graft survival depends on the ability of the recipe of not rejecting the “foreign organ”. Rejection is a naturally occurring process triggered by a biological response of the immune system, which main function in the body is to defend it against infectious organisms and other invaders. As such, the immune system is prepared to reject a “foreign organ”, something that is nowadays prevented by prescribing immunosuppressive therapies to the patients for their whole life. However, the use of immunosuppressive therapies entails important problems. On one side, suppressing the immune system implies severe side effects like opportunistic infections, cancer and other severe malignancies. On the other side, even under immunosuppressive therapies, about 50% of transplanted kidneys are lost during the first 10 years and this is because of an immune response usually described as chronic rejection. Therefore, the major challenges in ESKD deal with avoiding the side effects associated with immunosuppressant drugs and avoiding chronic rejection. In the TRANSBIO project we aim at bringing to the healthcare market a technology for efficient clinical management of patients undergoing a kidney transplant based on a simple and non-invasive blood test. Considering that worldwide, the number of people receiving renal transplantation annually is estimated at about 80,000 people, growing by approximately 6% annually and representing a prevalence of about 700 patients per million population, or what is the same about 5 million people living with a transplanted kidney, the TRANSBIO business opportunity seems unquestionable. Ámbito científico ciencias médicas y de la saludciencias de la saludsalud pública y medio ambientalciencias médicas y de la saludmedicina básicainmunologíaciencias médicas y de la saludciencias de la saludmedicina personalizadaciencias médicas y de la saludmedicina clínicatrasplanteciencias médicas y de la saludmedicina clínicanefrologíaenfermedad renal Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-2-2016-2017 Régimen de financiación SME-2 - SME instrument phase 2 Coordinador BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL Aportación neta de la UEn € 3 845 140,00 Dirección Calle santiago grisolia 2 parque tecnologico de madrid 28760 Tres cantos madrid España Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Comunidad de Madrid Comunidad de Madrid Madrid Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Otras fuentes de financiación € 1 500,86
